Related Experiment Video

Updated: Oct 1, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.8K

Retracted: Targeting Transforming Growth Factor-Beta1 (TGF-β1) Inhibits Tumorigenesis of Anaplastic Thyroid Carcinoma

Qiang Yin1, Shan Liu1, Anbing Dong2

  • 1Department of Oncology, People's Hospital of Rizhao, Rizhao, Shandong, China (mainland).

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|March 4, 2022
PubMed

Insights

This study on anaplastic thyroid carcinoma is retracted because key experiments, including TGF-ß1 and RT-PCR, could not be replicated. The authors requested retraction to maintain scientific integrity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy.
  • Understanding the molecular mechanisms driving ATC tumorigenesis is crucial for developing effective therapies.
  • Transforming Growth Factor-Beta1 (TGF-ß1) signaling pathways are implicated in various cancers.

Purpose of the Study:

  • To investigate the role of TGF-ß1 in inhibiting anaplastic thyroid carcinoma cell tumorigenesis.
  • To elucidate the specific signaling pathways involved in TGF-ß1's anti-tumorigenic effects.

Main Methods:

  • In vitro experiments were conducted to assess the effects of TGF-ß1.
  • Reverse Transcription Polymerase Chain Reaction (RT-PCR) was used to analyze gene expression.
  • The study aimed to explore the ERK1/2-NFkappakB-PUMA signaling cascade.

Main Results:

  • The in vitro experiments involving TGF-ß1 could not be successfully repeated.
  • The results obtained from RT-PCR analyses were not reproducible.
  • These reproducibility issues led to the decision to retract the study.

Conclusions:

  • Due to the inability to replicate critical experimental findings, the study's conclusions regarding TGF-ß1's role in ATC are invalidated.
  • The authors initiated a retraction to uphold scientific accuracy and prevent the dissemination of unverified results.
  • This situation underscores the importance of experimental reproducibility in scientific research.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.4K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K